Jobs / United States / Regeneron Pharmaceuticals INC
Senior Director, Life Cycle Management Lead - Oncology
Regeneron Pharmaceuticals INC · 🇺🇸 SLEEPY HOLLOW
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 290 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 40 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Regeneron Pharmaceuticals INC paid sponsored hires in similar roles6 certified filings for “Director IT Operations Management” (Computer and Information Systems Managers) in NJ: $220k–$263k, median $236k. Most were filed at wage level II (50%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Regeneron Pharmaceuticals INC
The US Department of Labor certified 290 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 40 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Regeneron Pharmaceuticals INC →
About the role
Build our future together: The Senior Director, Global Skin Cancer Life Cycle Management (LCM) Lead is a member of the Oncology Business Unit at Regeneron, responsible for leading life cycle management strategy and planning for all in-line oncology assets within the Skin Cancer tumor area. This leader is a highly strategic, business-focused expert who assesses opportunities and threats for brands in a fast-paced, complex market. This role reports directly to the Executive Director of Global Skin Cancer Marketing. The LCM Lead will collaborate closely with cross-functional teams and support the overall strategic goals of the portfolio, playing a critical role in Commercial/Clinical cross-functional forums. This individual needs to have strong communication and collaboration skills and will be in involved with leading activities across indications. Based on business needs, support of programming and process across total brand indications is required, which includes managing timelines and eliciting content from the Lung franchise for overall deliverable completion. Examples of select content includes summary reports and planning documents that are applicable across brand indications which are evaluated on a case-by-case basis. When & where: • On site in Sleepy Hollow, NY for 4 days a week Discover your role: • Facilitate development of and evolution of the global life cycle management strategy (e.g., indication sequencing, geographic expansion) for all in-line oncology assets with Skin Cancer indications to maintain competitive advantage. • Shape asset plans within Skin Cancer indications in coordination with the Executive Director of Global Skin Cancer Marketing, Regulatory, Clinical, Competitive Intelligence (CI), and other cross-functional partners; partner with US and international marketers to inform and align on the LCM plan. • Maintain up-to-date tumor landscape outlooks for our portfolio and potential competitors in relevant current and future areas, working with Clinical, CI, and Commercial Insights. • Share current CI with Global, US, and international marketers and country teams; develop global action plans for competitive threats to be implemented at the country level; develop and deliver related content (e.g., action memos on competitor approvals). • Support the Executive Director of Global Skin Cancer Marketing in developing the Commercial perspective for Skin Cancer assets in decision-making forums (e.g., Commercial/Clinical cross-functional committees) and cross-tumor planning meetings; help prepare for these meetings and support follow-up actions. • Lead the Marketing team’s efforts to plan cross-functionally for new indication launches from early development through pre-launch readiness, following established internal processes including identifying working groups cross functionally and across global and country/international teams to facilitate plans and decisions • Inform Medical Affairs and related teams of key data needs and future development plans the organization will support. • Develop business analyses/cases for Business Development purposes, for assessing indication trials, and for senior management reviews. • Serve as the key Marketing point of contact for the Business Development team on Skin Cancer strategy. • Contribute to labeling review team preparations, providing commercial insights to inform labeling decisions. • Analyze customer insights, monitor brand performance and competitive dynamics, and translate findings into marketing strategy to address customer needs. • Leverage customer feedback through formal and informal channels (e.g., advisory boards, KOL meetings at congresses, market research, field intelligence) to shape strategy and competitive differentiation. • Serve as a